Neoteryx Revenue and Competitors
Estimated Revenue & Valuation
- Neoteryx's estimated annual revenue is currently $3.1M per year.
- Neoteryx's estimated revenue per employee is $155,000
Employee Data
- Neoteryx has 20 Employees.
- Neoteryx grew their employee count by -17% last year.
Neoteryx's People
Name | Title | Email/Phone |
---|---|---|
1 | Founder & CEO | Reveal Email/Phone |
2 | Chief Scientific Officer | Reveal Email/Phone |
3 | Sales Operations Manager | Reveal Email/Phone |
4 | Customer Success Project Manager | Reveal Email/Phone |
5 | Research Scientist | Reveal Email/Phone |
6 | Marketing | Reveal Email/Phone |
Neoteryx Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Neoteryx?
Neoteryx is a biotechnology company specializing in providing tools for remote specimen collection and microsampling. The Mitra® device is the company's flagship product, based on volumetric absorptive microsampling (VAMS®) technology. The Mitra® device is intended as a specimen collector and for the storage and transport of biological fluids. In the US, use of the Mitra® device with blood is limited to research and non-diagnostic applications. In many countries outside the US, the Mitra device is approved as a remote blood sample collection device for some clinical applications, as referenced in some content posted here.
keywords:N/AN/A
Total Funding
20
Number of Employees
$3.1M
Revenue (est)
-17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4.1M | 20 | -55% | N/A |
#2 | $2M | 20 | 5% | N/A |
#3 | $2.9M | 20 | -13% | N/A |
#4 | $4.1M | 20 | -47% | N/A |
#5 | $2M | 20 | 11% | N/A |